NOVEMBER 2024LIFE SCIENCES REVIEW8IN MY OPINIONIN MY OPINIONBy Tamara J. Laskowski, Global Head, Clinical & Process Development, Lonza Personalized Medicine, LonzaCONQUERING CHALLENGES AND BROADENING OPPORTUNITIES: THE JOURNEY TO BRINGING INNOVATIVE CELL THERAPIES TO PATIENTSThe journey to an innovative therapy: CAR-T cellsT cells equipped with a Chimeric Antigen Receptor, known as CAR-T cells, have had an extraordinary impact on the oncology field. Famously recognized in clinical, scientific, and mainstream circles, CAR-T cells have ushered in a new era in the treatment of advanced, relapsed/refractory blood cancers. Many patients, who were enduring the painful realization that they might lose their fight with cancer after conventional methods of cancer treatment had failed, experienced life-restoring transformation upon receiving an infusion of their own CAR-T cells. Over a decade into many CAR-T treatments, we see reports of decade-long sustained remissions which suggest potential cures for diseases that had long been deemed incurable. At the heart of CAR-T cell therapy is an elegantly simple premise: we can harness the intrinsic power of immune cells and equip them with the necessary tools to unleash a destructive force capable of eradicating certain forms of cancer. Despite the appearance of simplicity, the most common method of creating a CAR-T cell involves a complex, extensive, and costly manufacturing process that starts with the extraction of the patient's own T cells. This poses the first challenge. Patients with advanced, metastatic cancers have often received multiple lines of therapy prior to CAR-T, and, as a result, are rendered immunocompromised, possessing fewer T cells that are weaker in function. Taking these cells through the required genetic editing steps and rapid expansion phase constitutes a new set of challenges. Not all manufactures succeed, and thus, not all patients, unfortunately, receive their therapy. In a relatively short amount of time, clinicians and scientists have advanced the concept of transforming one's own immune cells into potent anti-cancer agents and moved rapidly toward bringing these innovative therapies to hospitals around the world. Leveraging strong science, compelling clinical data, and unwavering determination, CAR-T cell pioneers forged a path through regulatory approval, and cleared the way for CAR-T cell therapy to enter the market. The year 2017 marked the arrival of Kymriah and Yescarta - the first commercial CAR-T products targeting advanced lymphoma and acute lymphoblastic leukemia. Building on what was learned from these successes, the next five years brought forth four new CAR-T therapies, further expanding the arsenal of cell-based treatments against cancer. Challenges and new opportunitiesDespite the unprecedented successes seen in the CAR-T journey and the accelerated pace at which the field has advanced in this past decade, many challenges still remain. CAR-T cells have not yet shown the same efficacy in solid tumors as seen for blood cancers. This may be largely due to the inherently complex nature of the solid tumor microenvironment, where an abundance of suppressive signals and diminished oxygenation weaken the immune response. Aware of these obstacles, the field turned to new strategies, seeking to leverage tumor-fighting capabilities of other cells of the immune system. Soon, CAR-T cells were joined by CAR-NK (natural killer cells), CAR-NKT (natural killer T cells), and CAR-M (macrophages). Moreover, supported by advancements in single-cell multiomics, insights into the genetics and epigenetics of tumor and immune cells have helped to elucidate new functionalities that can be further engineered into CAR-modified cell therapies. Bringing novel therapies to patients faster Today, a growing number of next-generation products are advancing through the pre-clinical and clinical development phases. To broaden patient access to these potentially
< Page 7 | Page 9 >